<DOC>
	<DOCNO>NCT00617565</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial investigate efficacy biphasic insulin aspart 30 postprandial glycaemic control .</brief_summary>
	<brief_title>Efficacy Safety Biphasic Insulin Aspart 30 Type 1 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 2 diabetes least 3 month Stabilised current treatment premixed human insulin least 4 week Body mass index ( BMI ) 1840 kg/m2 HbA1c 13.0 % Able willing perform selfblood glucose monitor The receipt investigational drug within last three month prior trial Has history drug abuse alcohol dependence within last 5 year Active proliferative retinopathy require laser surgical intervention within last year Recurrent major hypoglycaemia judge Investigator Known suspect allergy trial product related product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>